Precision in Progress: Optimizing Treatment Strategies in Platinum-Resistant Ovarian Cancer

MICROLEARNING
0.75 AMA PRA Credits
Overview
Learning Objectives
CME/ Information
Faculty and Disclosures
Instructions

Program Overview

Platinum-resistant ovarian cancer (PROC) remains a complex and evolving treatment landscape, requiring clinicians to make timely, evidence-based decisions across multiple lines of therapy. Advances in antibody-drug conjugates (ADCs), PARP inhibitors (PARPis), and immunotherapies have expanded treatment options, but also introduced challenges in biomarker interpretation, therapy sequencing, and toxicity management. Integrating these considerations while maintaining a patient-centered approach is essential to optimizing outcomes.

In this microlearning activity, you will begin with brief faculty-led instruction highlighting key concepts in the management of PROC, including biomarker-driven treatment selection, sequencing strategies, and adverse event management. You will then apply these insights in an interactive patient encounter designed to reinforce clinical reasoning and real-world decision-making.

This case-based activity offers a practical opportunity to translate emerging evidence into personalized treatment strategies, strengthening confidence in managing patients with PROC.

Target Audience

This activity is intended for U.S.-based gynecologic oncologists, medical oncologists, pathologists, obstetrician-gynecologists (OBGYNs), and other clinicians involved in the care of patients with ovarian cancer, including oncology advanced practice providers (APPs), oncology pharmacists, oncology nurses, and genetic counselors.

Secondary Audience:
Ophthalmologists, particularly those involved in the co-management of ocular toxicities associated with novel therapies such as antibody-drug conjugates (ADCs).

Supporter Acknowledgement

This educational activity is supported by an independent educational grant from AbbVie Inc.

Learning Objectives

Upon completion of this activity, the participant should be able to:
  • Describe the mechanism of action of novel therapeutic agents such as ADCs, PARPi and immunotherapies used in the treatment of PROC.
  • Evaluate the role of biomarkers in guiding therapy selection, monitoring treatment response and stratifying patients for personalized care.
  • Outline an individualized approach to treatment selection for patients with platinum-resistant ovarian cancer by integrating clinical characteristics, treatment history, and tumor molecular profiling to guide evidence-based use of standard and emerging therapies.
  • Translate data from recent and emerging clinical trials in PROC to optimize evidence-based treatment sequencing and patient selection.

Accredited Provider

This activity is jointly provided by Global Education Group and Iridium Continuing Education.

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Iridium. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty, Staff, and Planners’ Disclosures

Global
The planners and managers at Global Education Group have no relevant financial relationships to disclose.

Iridium
The planners and managers at Iridium have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Iridium do not recommend the use of any agent outside of the labeled indications.The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosures of Relevant Financial Relationship(s)

​Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:
Kathleen Moore, MD, MS, FASCO
Deputy Director, OU Health Stephenson Cancer Center
Director, Oklahoma TSET Phase I Program
Professor of Gynecologic Oncology
The University of Oklahoma College of Medicine
Oklahoma City, OK

Disclosures
Consulting Fee (e.g., Advisory Board): Abbvie, Astra Zeneca, Aadi, BioNTech, Caris, Corcept, Duality, Daiichi-Sankyo, Eisai, GSK, Genmab, Immunogen, Iovance, Janssen, Loxo/Lilly, Merck, Mersana, Novartis, Pannavance, Regeneron, Schrodinger, Takeda, Verastem, Whitehawk, Zentalis, Zymeworks
Contracted Research (Principal Investigators must provide information, even if received by the institution): Astra Zeneca, Verastem, GSK, Schrodinger, Daiichi-Sankyo, TORL, Allarity, Zymeworks

Instructions to Receive Credit

In order to receive credit for this activity, the participant must: 

  • Read the learning objectives and faculty disclosures Complete the pretest
  • Participate in the on-demand activity
  • Complete the posttest with a score of 70% or higher
  • Complete the evaluation

A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.

Fee Information and Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

System Requirements

System requirements
This educational activity is supported by an independent educational grant from AbbVie Inc.

Maximum Credit Amount: 0.75

Credit Type: ACCME
Release: April 13, 2026
Expiration: October 13, 2026